See today's BioWorld
To read the full story, subscribe or sign in.

Nibec stock soars 30% on $435M peptide deal with US biotech

May 29, 2025
By Marian (YoonJee) Chu
No Comments
Nibec Co. Ltd. announced May 28 the signing of a potential $435 million license deal for NP-201, its phase II-ready peptide-based pulmonary fibrosis therapy candidate, with an undisclosed U.S.-based biotech company.
BioWorld Deals and M&A Newco news Cancer Gastrointestinal Inflammatory Obesity Peptide Asia-Pacific Australia U.S. TGA